Anxiolytic-like effects after vector-mediated overexpression of neuropeptide Y in the amygdala and hippocampus of mice

Neuropeptides

Volumn 48, Issue 6, 2014, Pages 335-344

  Christiansen, S H ^a   Olesen, M V ^a   Gotzsche C R ^a   Woldbye, D P D ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Amygdala; Anxiety; Depression; Hippocampus; RAAV NPY

Indexed keywords

ANXIOLYTIC AGENT; MESSENGER RNA; NEUROPEPTIDE Y; PARVOVIRUS VECTOR;

ADULT; AMYGDALOID NUCLEUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIDEPRESSANT ACTIVITY; ARTICLE; CONTROLLED STUDY; DEPRESSION; ELEVATED PLUS MAZE TEST; EMOTION; FOOD INTAKE; FORCED SWIM TEST; GENE OVEREXPRESSION; GENETIC TRANSDUCTION; HIPPOCAMPUS; LATERAL HYPOTHALAMUS; LIGHT-DARK TEST; MALE; MEDIAL AMYGDALA; MOUSE; NONHUMAN; OPEN FIELD TEST; TAIL SUSPENSION TEST; TRANQUILIZING ACTIVITY; TRANSGENE; VIRAL GENE THERAPY; WEIGHT GAIN; ADMINISTRATION AND DOSAGE; ANIMAL; ANXIETY; BIOSYNTHESIS; DEPENDOPARVOVIRUS; GENE VECTOR; GENETICS; METABOLISM; MOTOR ACTIVITY; VIROLOGY;

MUS; RODENTIA;

AMYGDALA; ANIMALS; ANTI-ANXIETY AGENTS; ANXIETY; DEPENDOVIRUS; DEPRESSION; GENETIC VECTORS; HIPPOCAMPUS; MALE; MICE; MOTOR ACTIVITY; NEUROPEPTIDE Y;

EID: 84919495134     PISSN: 01434179     EISSN: 15322785     Source Type: Journal    
DOI: 10.1016/j.npep.2014.09.004     Document Type: Article

References (81)

1. Alexander B., Warner-Schmidt J., Eriksson T.M., Tamminga C., Arango-Lievano M., Ghose S., et al. Reversal of depressed behaviors in mice by p11 gene therapy in the nucleus accumbens. Sci. Transl. Med 2010, 2.
2. Alvarez R.P., Biggs A., Chen G., Pine D.S., Grillon C. Contextual fear conditioning in humans: cortical-hippocampal and amygdala contributions. J. Neurosci 2008, 28:6211-6219.
3. Bolwig T.G., Woldbye D.P.D., Mikkelsen J.D. Electroconvulsive therapy as an anticonvulsant: a possible role of neuropeptide Y (NPY). J. ECT 1999, 15:93-101.
4. Caberlotto L., Fuxe K., Overstreet D.H., Gerrard P., Hurd Y.L. Alterations in neuropeptide Y and Y1 receptor mRNA expression in brains from an animal model of depression: region specific adaptation after fluoxetine treatment. Brain Res. Mol. Brain Res 1998, 59:58-65.
5. Christensen D.Z., Olesen M.V., Kristiansen H., Mikkelsen J.D., Woldbye D.P. Unaltered neuropeptide Y (NPY)-stimulated [35S]GTPgammaS binding suggests a net increase in NPY signalling after repeated electroconvulsive seizures in mice. J. Neurosci. Res 2006, 84:1282-1291.
6. Christiansen S.H., Woldbye D.P.D. Regulation of the galanin system by repeated electroconvulsive seizures in mice. J. Neurosci. Res 2010, 88:3635-3643.
7. Christiansen S.H., Olesen M.V., Wörtwein G., Woldbye D.P.D. Fluoxetine reverts chronic restraint stress-induced depression-like behaviour and increases neuropeptide Y and galanin expression in mice. Behav. Brain Res 2011, 216:585-591.
8. Cryan J.F., Holmes A. The ascent of mouse: advances in modeling human depression and anxiety. Nat. Rev. Drug Discov 2005, 4:775-790.
9. Cryan J.F., Mombereau C., Vassout A. The tail suspension test as a model for assessing antidepressant activity: review of pharmacological and genetic studies in mice. Neurosci. Biobehav. Rev 2005, 29:571-625.
10. Deo G.S., Dandekar M.P., Upadhya M.A., Kokare D.M., Subhedar N.K. Neuropeptide Y Y1 receptors in the central nucleus of amygdala mediate the anxiolytic-like effect of allopregnanolone in mice: behavioral and immunocytochemical evidences. Brain Res 2010, 1318:77-86.
11. Felix-Ortiz A.C., Beyeler A., Seo C., Leppla C.A., Wildes C.P., Tye K.M. BLA to vHPC inputs modulate anxiety-related behaviors. Neuron 2013, 79:658-664.
12. Fendt M., Burki H., Imobersteg S., Lingenhohl K., McAllister K.H., Orain D., et al. Fear-reducing effects of intra-amygdala neuropeptide Y infusion in animal models of conditioned fear: an NPY Y1 receptor independent effect. Psychopharmacology (Berl) 2009, 206:291-301.
13. Gjerris A., Widerlöv E., Werdelin L., Ekman R. Cerebrospinal fluid concentrations of neuropeptide Y in depressed patients and in controls. J. Psychiatry Neurosci 1992, 17:23-27.
14. Gøtzsche C.R., Sørensen A.T., Nikitidou L., Olesen M.V., Sørensen G., Christiansen S.H., et al. Combined gene overexpression of neuropeptide Y and its receptor Y5 in the hippocampus suppresses seizures. Neurobiol. Dis 2012, 45:288-296.
15. Gutman A.R., Yang Y., Ressler K.J., Davis M. The role of neuropeptide Y in the expression and extinction of fear-potentiated startle. J. Neurosci 2008, 28:12682-12690.
16. Haas K.Z., Sperber E.F., Moshé S.L. Kindling in developing animals: interactions between ipsilateral loci. Brain Res. Dev. Brain Res 1992, 68:140-143.
17. Heilig M. The NPY system in stress, anxiety and depression. Neuropeptides 2004, 38:213-224.
18. Heilig M., Soderpalm B., Engel J.A., Widerlov E. Centrally administered neuropeptide Y (NPY) produces anxiolytic-like effects in animal anxiety models. Psychopharmacology (Berl) 1989, 98:524-529.
19. Heilig M., McLeod S., Brot M., Heinrichs S.C., Menzaghi F., Koob G.F., et al. Anxiolytic-like action of neuropeptide Y: mediation by Y1 receptors in amygdala, and dissociation from food intake effects. Neuropsychopharmacology 1993, 8:357-363.
20. Heilig M., Zachrisson O., Thorsell A., Ehnvall A., Mottagui-Tabar S., Sjögren M., et al. Decreased cerebrospinal fluid neuropeptide Y (NPY) in patients with treatment refractory unipolar depression: preliminary evidence for association with preproNPY gene polymorphism. J. Psychiatr. Res 2004, 38:113-121.
21. Hudry E., Van D.D., Kulik W., De Deyn P.P., Stet F.S., Ahouansou O., et al. Adeno-associated virus gene therapy with cholesterol 24-hydroxylase reduces the amyloid pathology before or after the onset of amyloid plaques in mouse models of Alzheimer's disease. Mol. Ther 2010, 18:44-53.
22. Husum H., Mikkelsen J.D., Hogg S., Mathe A.A., Mork A. Involvement of hippocampal neuropeptide Y in mediating the chronic actions of lithium, electroconvulsive stimulation and citalopram. Neuropharmacology 2000, 39:1463-1473.
23. Husum H., Vasquez P.A., Mathé A.A. Changed concentrations of tachykinins and neuropeptide Y in brain of a rat model of depression: lithium treatment normalizes tachykinins. Neuropsychopharmacology 2001, 24:183-191.
24. Ishida H., Shirayama Y., Iwata M., Katayama S., Yamamoto A., Kawahara R., et al. Infusion of neuropeptide Y into CA3 region of hippocampus produces antidepressant-like effect via Y1 receptor. Hippocampus 2007, 17:271-280.
25. Jiménez-Vasquez P.A., Overstreet D.H., Mathé A.A. Neuropeptide Y in male and female brains of Flinders sensitive line, a rat model of depression. Effects of electroconvulsive stimuli. J. Psychiatr. Res 2000, 34:405-412.
26. Kaplitt M.G., Feigin A., Tang C., Fitzsimons H.L., Mattis P., Lawlor P.A., et al. Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial. Lancet 2007, 369:2097-2105.
27. Karl T., Duffy L., Herzog H. Behavioural profile of a new mouse model for NPY deficiency. Eur. J. Neurosci 2008, 28:173-180.
28. Koefoed P., Woldbye D.P.D., Hansen T.V.O., Christiansen S.H., Mors O., Kessing L.V., et al. Association of the leucine-7 to proline-7 variation in the signal sequence of neuropeptide Y with major depression. Acta Neuropsychiatr 2012, 24:81-90.
29. Kormos V., Gaszner B. Role of neuropeptides in anxiety, stress, and depression: from animals to humans. Neuropeptides 2013, 47:401-419.
30. Levine A.S., Jewett D.C., Cleary J.P., Kotz C.M., Billington C.J. Our journey with neuropeptide Y: effects on ingestive behaviors and energy expenditure. Peptides 2004, 25:505-510.
31. Lim W.C., Seo J.M., Lee C.I., Pyo H.B., Lee B.C. Stimulative and sedative effects of essential oils upon inhalation in mice. Arch. Pharm. Res 2005, 28:770-774.
32. Lin E.J., Sainsbury A., Lee N.J., Boey D., Couzens M., Enriquez R., et al. Combined deletion of Y1, Y2, and Y4 receptors prevents hypothalamic neuropeptide Y overexpression-induced hyperinsulinemia despite persistence of hyperphagia and obesity. Endocrinology 2006, 147:5094-5101.
33. Lin E.-J.D., Young D., Baer K., Herzog H., During M.J. Differential actions of NPY on seizure modulation via Y1 and Y2 receptors: evidence from receptor knockout mice. Epilepsia 2006, 47:773-780.
34. Lin E.J., Lin S., Aljanova A., During M.J., Herzog H. Adult-onset hippocampal-specific neuropeptide Y overexpression confers mild anxiolytic effect in mice. Eur. Neuropsychopharmacol 2010, 20:164-175.
35. Manfredsson F.P., Mandel R.J. Development of gene therapy for neurological disorders. Discov. Med 2010, 9:204-211.
36. Martínez-García F., Novejarque A., Gutiérrez-Castellanos N., Lanuza E. Piriform cortex and amygdala. The Mouse Nervous System 2012, Academic Press, London. C. Watson, G. Paxinos, L. Puelles (Eds.).
37. Mathe A.A. Neuropeptides and electroconvulsive treatment. J. ECT 1999, 15:60-75.
38. McCown T.J. The future of epilepsy treatment: focus on adeno-associated virus vector gene therapy. Drug News Perspect 2010, 23:281-286.
39. Melas P.A., Lennartsson A., Vakifahmetoglu-Norberg H., Wei Y., Aberg E., Werme M., et al. Allele-specific programming of NPY and epigenetic effects of physical activity in a genetic model of depression. Transl. Psychiatry 2013, 3:e255.
40. Mickey B.J., Zhou Z., Heitzeg M.M., Heinz E., Hodgkinson C.A., Hsu D.T., et al. Emotion processing, major depression, and functional genetic variation of neuropeptide Y. Arch. Gen. Psychiatry 2011, 68:158-166.
41. Mikkelsen J.D., Woldbye D.P. Accumulated increase in neuropeptide Y and somatostatin gene expression of the rat in response to repeated electroconvulsive stimulation. J. Psychiatr. Res 2006, 40:153-159.
42. Mikkelsen J.D., Woldbye D.P.D., Kragh J., Larsen P.J., Bolwig T.G. Electroconvulsive shocks increase the expression of neuropeptide Y (NPY) mRNA in the piriform cortex and the dentate gyrus. Brain Res. Mol. Brain Res 1994, 23:317-322.
43. Mitra R., Sapolsky R.M. Gene therapy in rodent amygdala against fear disorders. Expert Opin. Biol. Ther 2010, 10:1289-1303.
44. Morales-Medina J.C., Dumont Y., Quirion R. A possible role of neuropeptide Y in depression and stress. Brain Res 2010, 1314:194-205.
45. Morales-Medina J.C., Yvan D., Charles-Etienne B., Bastianetto S., Flores G., Fournier A., et al. Role of neuropeptide Y Y1 and Y2 receptors on behavioral despair in a rat model of depression with co-morbid anxiety. Neuropharmacology 2012, 62:200-208.
46. Nikisch G., Mathé A.A. CSF monoamine metabolites and neuropeptides in depressed patients before and after electroconvulsive therapy. Eur. Psychiatry 2008, 23:356-359.
47. Nikisch G., Agren H., Eap C.B., Czernik A., Baumann P., Mathé A.A. Neuropeptide Y and corticotropin-releasing hormone in CSF mark response to antidepressive treatment with citalopram. Int. J. Neuropsychopharmacol 2005, 8:403-410.
48. Olesen M.V., Christiansen S.H., Gøtzsche C.R., Nikitidou L., Kokaia M., Woldbye D.P.D. Neuropeptide Y Y1 receptor hippocampal overexpression via viral vectors is associated with modest anxiolytic-like and proconvulsant effects in mice. J. Neurosci. Res 2012, 90:498-507.
49. Olesen M.V., Christiansen S.H., Gøtzsche C.R., Holst B., Kokaia M., Woldbye D.P. Y5 neuropeptide Y receptor overexpression in mice neither affects anxiety- and depression-like behaviours nor seizures but confers moderate hyperactivity. Neuropeptides 2012, 46:71-79.
50. Overstreet D.H. Modeling depression in animal models. Methods Mol. Biol 2012, 829:125-144.
51. Painsipp E., Wultsch T., Edelsbrunner M.E., Tasan R.O., Singewald N., Herzog H., et al. Reduced anxiety-like and depression-related behavior in neuropeptide Y Y4 receptor knockout mice. Genes Brain Behav 2008, 7:532-542.
52. Paxinos G., Franklin K. The Mouse Brain - in Stereotaxic Coordinates 2001, Academic Press, San Diego.
53. Pitkänen A., Pikkarainen M., Nurminen N., Ylinen A. Reciprocal connections between the amygdala and the hippocampal formation, perirhinal cortex, and postrhinal cortex in rat: a review. Ann. N. Y. Acad. Sci 2000, 911:369-391.
54. Porsolt R.D., Bertin A., Jalfre M. Behavioral despair in mice: a primary screening test for antidepressants. Arch. Int. Pharmacodyn. Ther 1977, 229:327-336.
55. Primeaux S.D., Wilson S.P., Cusick M.C., York D.A., Wilson M.A. Effects of altered amygdalar neuropeptide Y expression on anxiety-related behaviors. Neuropsychopharmacology 2005, 30:1589-1597.
56. Redrobe J.P., Dumont Y., Fournier A., Quirion R. The neuropeptide Y (NPY) Y1 receptor subtype mediates NPY-induced antidepressant-like activity in the mouse forced swimming test. Neuropsychopharmacology 2002, 26:615-624.
57. Riban V., Fitzsimons H.L., During M.J. Gene therapy in epilepsy. Epilepsia 2009, 50:24-32.
58. Richichi C., Lin E.J., Stefanin D., Colella D., Ravizza T., Grignaschi G., et al. Anticonvulsant and antiepileptogenic effects mediated by adeno-associated virus vector neuropeptide Y expression in the rat hippocampus. J. Neurosci 2004, 24:3051-3059.
59. Sajdyk T.J., Vandergriff M.G., Gehlert D.R. Amygdalar neuropeptide Y Y1 receptors mediate the anxiolytic-like actions of neuropeptide Y in the social interaction test. Eur. J. Pharmacol 1999, 368:143-147.
60. Sajdyk T.J., Schober D.A., Gehlert D.R. Neuropeptide Y receptor subtypes in the basolateral nucleus of the amygdala modulate anxiogenic responses in rats. Neuropharmacology 2002, 43:1165-1172.
61. Sajdyk T.J., Schober D.A., Smiley D.L., Gehlert D.R. Neuropeptide Y-Y2 receptors mediate anxiety in the amygdala. Pharmacol. Biochem. Behav 2002, 71:419-423.
62. Schmidt C., Gobaille S., Hechler V., Schmitt M., Bourguignon J.J., Maitre M. Anti-sedative and anti-cataleptic properties of NCS-382, a [gamma]-hydroxybutyrate receptor antagonist. Eur. J. Pharmacol 1991, 203:393-397.
63. Schmidt L.S., Thomsen M., Weikop P., Dencker D., Wess J., Woldbye D.P.D., et al. Increased cocaine self-administration in M4 muscarinic acetylcholine receptor knockout mice. Psychopharmacology (Berl) 2011, 216:367-378.
64. Sehlmeyer C., Schoning S., Zwitserlood P., Pfleiderer B., Kircher T., Arolt V., et al. Human fear conditioning and extinction in neuroimaging: a systematic review. PLoS ONE 2009, 4:e5865.
65. Slawecki C.J., Thorsell A.K., El Khoury A., Mathé A.A., Ehlers C.L. Increased CRF-like and NPY-like immunoreactivity in adult rats exposed to nicotine during adolescence: relation to anxiety-like and depressive-like behavior. Neuropeptides 2005, 39:369-377.
66. Sørensen A.T., Nikitidou L., Ledri M., Lin E.J., During M.J., Kanter-Schlifke I., et al. Hippocampal NPY gene transfer attenuates seizures without affecting epilepsy-induced impairment of LTP. Exp. Neurol 2009, 215:328-333.
67. Sørensen G., Lindberg C., Wörtwein G., Bolwig T.G., Woldbye D.P.D. Differential roles for neuropeptide Y Y1 and Y5 receptors in anxiety and sedation. J. Neurosci. Res 2004, 77:723-729.
68. Stenfors C., Theodorsson E., Mathé A.A. Effect of repeated electroconvulsive treatment on regional concentrations of tachykinins, neurotensin, vasoactive intestinal polypeptide, neuropeptide Y, and galanin in rat brain. J. Neurosci. Res 1989, 24:445-450.
69. Steru L., Chermat R., Thierry B., Simon P. The tail suspension test: a new method for screening antidepressants in mice. Psychopharmacology (Berl) 1985, 85:367-370.
70. Stogner K.A., Holmes P.V. Neuropeptide-Y exerts antidepressant-like effects in the forced swim test in rats. Eur. J. Pharmacol 2000, 387:R9-R10.
71. Tasan R.O., Nguyen N.K., Weger S., Sartori S.B., Singewald N., Heilbronn R., et al. The central and basolateral amygdala are critical sites of neuropeptide Y/Y2 receptor-mediated regulation of anxiety and depression. J. Neurosci 2010, 30:6282-6290.
72. Thorsell A., Michalkiewicz M., Dumont Y., Quirion R., Caberlotto L., Rimondini R., et al. Behavioral insensitivity to restraint stress, absent fear suppression of behavior and impaired spatial learning in transgenic rats with hippocampal neuropeptide Y overexpression. Proc. Natl Acad. Sci. U.S.A. 2000, 97:12852-12857.
73. Thorsell A., Repunte-Canonigo V., O'Dell L.E., Chen S.A., King A.R., Lekic D., et al. Viral vector-induced amygdala NPY overexpression reverses increased alcohol intake caused by repeated deprivations in Wistar rats. Brain 2007, 130:1330-1337.
74. Tiesjema B., Adan R.A., Luijendijk M.C., Kalsbeek A., la Fleur S.E. Differential effects of recombinant adeno-associated virus-mediated neuropeptide Y overexpression in the hypothalamic paraventricular nucleus and lateral hypothalamus on feeding behavior. J. Neurosci 2007, 27:14139-14146.
75. Verma D., Tasan R.O., Herzog H., Sperk G. NPY controls fear conditioning and fear extinction by combined action on Y1 and Y2 receptors. Br. J. Pharmacol 2012, 166:1461-1473.
76. Wahlestedt C., Blendy J.A., Kellar K.J., Heilig M., Widerlöv E., Ekman R. Electroconvulsive shocks increase the concentration of neocortical and hippocampal neuropeptide Y (NPY)-like immunoreactivity in the rat. Brain Res 1990, 507:65-68.
77. Widerlöv E., Lindstrom L.H., Wahlestedt C., Ekman R. Neuropeptide Y and peptide YY as possible cerebrospinal fluid markers for major depression and schizophrenia, respectively. J. Psychiatr. Res 1988, 22:69-79.
78. Witter M. Hippocampus. The Mouse Nervous System 2012, Academic Press, London. C. Watson, G. Paxinos, L. Puelles (Eds.).
79. Woldbye D.P.D., Ängehagen M., Gøtzsche C.R., Elbrønd-Bek H., Sørensen A.T., Christiansen S.H., et al. Adeno-associated viral vector-induced overexpression of neuropeptide Y Y2 receptors in the hippocampus suppresses seizures. Brain 2010, 133:2778-2788.
80. Wu G., Feder A., Wegener G., Bailey C., Saxena S., Charney D., et al. Central functions of neuropeptide Y in mood and anxiety disorders. Expert Opin. Ther. Targets 2011, 15:1317-1331.
81. Yamamoto Y., Tanahashi T., Kawai T., Chikahisa S., Katsuura S., Nishida K., et al. Changes in behavior and gene expression induced by caloric restriction in C57BL/6 mice. Physiol. Genomics 2009, 39:227-235.